Clinical genomics interpretation platforms market seen reaching $2.93 billion by 2030

The market for clinical genomics interpretation platforms is projected to grow from $1.52 billion in 2025 to $2.93 billion by 2030, driven by precision medicine, AI tools and broader genomic screening. North America led in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Clinical genomics interpretation platforms help clinicians turn genetic data into treatment decisions for personalized medicine and diagnostics. - Faster adoption could improve variant analysis, support precision therapies and speed diagnosis for patients with genetic disorders and cancers. - The market’s growth signals more spending on genomic infrastructure, analytics and clinical bioinformatics across healthcare systems.

What happened: - The Business Research Company said the global clinical genomics interpretation platforms market is projected to rise from $1.52 billion in 2025 to $1.74 billion in 2026. - The report forecasts the market will reach $2.93 billion by 2030. - The 2026 to 2030 period implies a 14.0% compound annual growth rate. - The company published the forecast on Sept. 7, 2026, in London. - The report is titled Clinical Genomics Interpretation Platforms Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - A free sample is available here. - The full report is available here.

The details: - The report ties recent growth to next-generation sequencing adoption, rising interest in personalized medicine, more genomic research funding, expanded clinical bioinformatics services and more genetic disorders and cancers. - The forecast period’s growth is expected to come from AI-powered genomic interpretation tools, precision therapy demand, cloud-based analytics, population-scale genomic screening and standardized interoperable genomic databases. - Key trends include AI-driven variant interpretation, automated clinical decision support, cloud-enabled large-scale sequencing analysis, multi-omics data integration, interoperable databases and real-time genomic reporting tools. - Clinical genomics interpretation platforms are software systems that analyze and manage genomic and molecular data for clinical and research use. - These platforms combine bioinformatics algorithms, databases, AI capabilities and analytical workflows to identify genetic variants and assess their clinical significance. - The platforms are designed to improve the accuracy, accessibility and consistency of genomic analysis. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - Precision medicine is becoming a stronger commercial driver because more therapies depend on matching treatment to a patient’s genetic profile. - The FDA approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022, according to the Personalized Medicine Coalition. - That jump suggests more clinical demand for tools that can process genomic data and connect results to treatment choices. - The region split points to mature demand in North America and faster expansion in markets still building genomic capacity.

What's next: - The report expects AI, cloud analytics and standardization efforts to shape the next phase of market growth. - Wider genomic screening programs could push these platforms deeper into routine care and public health programs. - More interoperable databases may make collaboration and large-scale research easier. - The Business Research Company says the report package includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspots infographics and updated graphics and tables.

The bottom line: - Clinical genomics interpretation platforms are moving from niche clinical tooling to a broader precision medicine infrastructure layer, with growth set to stay strong through 2030.